The Clostridioides Difficile Trial of REC-3964
Stopped early · Phase 2
Conditions studied: Recurrent Clostridioides Difficile Infection
In brief
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of REC-3964 (doses of either 250 mg or 500 mg PO every 12 hours) for the reduction of Clostridioides difficile infection (CDI).
Key facts
- Study ID
- NCT06536465
- Run by
- Recursion Pharmaceuticals Inc.
- People needed
- 3
- Starts
- 2024-10-14
- Expected to finish
- 2025-05-06
- Last updated by the study team
- 2025-11-17
Who can join
Age: 18 and older, up to 115. Sex: any. Healthy volunteers: not accepted.
Where it is running
- GANJ - Toms River - Ocean Family Gastroenterology — Toms River, New Jersey, United States
- Southern Star Research Institute, LLC — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.